Monitor initial commercial uptake and revenue contribution from TCAR procedures in upcoming quarters. The company also has an ongoing CGUARDIANS III trial for its proprietary SwitchGuard NPS, which if cleared could further strengthen its TCAR platform.
NSPR drugs
NSPR drug pipeline →How the stock moved after the report
⚠ Clustered BULLISH VIEWSTOCK BELOW ENTRY AT T+1- T+0 · Nov 13 $0.6441entry
- T+1 · yesterday −6.85%α −4.94% · $0.6000
- T+2 · todayOpen
- T+5 · in 3d Pending
- T+20 · in 27d Pending
- T+60 · in 3mo Pending
Price Chart
REPLAYWatch the reaction play outHow similar events traded
Executive Summary
InspireMD received FDA approval for its CGuard Prime TransCarotid Stent System for use in TCAR procedures, doubling the platform's U.S. addressable market to ~75,000 annual carotid stenting procedures. The approval was supported by the CGUARDIANS II trial showing 100% acute device success and zero adverse events at 30 days. This is a significant commercial milestone for the company, which has a $36M market cap and had been limited to CAS procedures.
Key Facts
- FDA approved PMA Supplement for CGuard Prime TransCarotid Stent System for TCAR procedures
- Approval doubles total addressable U.S. market to ~75,000 annual carotid stenting procedures (TCAR + CAS)
- CGUARDIANS II trial: 100% acute device success, zero deaths/strokes/MI/stent thrombosis at 30 days
- Over 35,000 TCAR procedures performed annually in the U.S.
- InspireMD is the first company with both CAS and TCAR delivery options for its carotid stent
- Company market cap is $36M; this is a first commercial approval for a new indication
Financial Impact
Doubles addressable U.S. market from ~40,000 CAS procedures to ~75,000 total carotid stenting procedures annually; company market cap $36M
Risk Factors
- Company has history of losses and going concern uncertainty; may need additional capital
- Voluntary recall of CGuard Prime 135 cm delivery system is ongoing and could impact commercial launch
- Competition from established TCAR players (Silk Road Medical/Enroute system) and other stent manufacturers
- SwitchGuard NPS is still investigational; TCAR approval currently relies on third-party embolic protection system
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3402142 |
Track record
29 reports on NSPR
5 of 8 bullish or bearish reports moved the stock their way by T+60. Best: +54.19% at T+60 after the Apr 3, 2026 report. 10 of 13 went positive at some point.
Filters
- Nov 17, 2026today Insider Cluster Mixed 5/10 Entry $0.6500 Now $0.6500 −0.00% settles Feb 17
- Nov 16, 20261d ago 8-K Bearish 6/10 Entry $0.6441 Now $0.6500 −0.92% settles Feb 12
- Nov 16, 20261d ago 424B5 Bearish 6/10 Entry $0.6441 Now $0.6500 −0.92% settles Feb 12
- Nov 13, 20264d ago Press Release Bearish 6/10 Entry $0.6441 Now $0.6500 −0.92% settles Feb 11
- Nov 12, 20264d ago 424B5 Bearish 6/10 Entry $0.6441 Now $0.6500 −0.92% settles Feb 11
- Nov 12, 20264d ago 8-K Bullish 7/10 No price data
- Nov 12, 20264d ago 8-K Bullish 6/10 Entry $0.6441 Now $0.6500 +0.92% settles Feb 11
- Nov 12, 20265d ago Press Release Bearish 5/10 Entry $0.6441 Now $0.6500 −0.92% settles Feb 11
- Nov 12, 20265d ago Press Release Bullish 7/10 Entry $0.6441 Now $0.6500 +0.92% settles Feb 11
- Nov 12, 20265d ago Press Release Bullish 8/10 Viewing Entry $0.6441 Now $0.6500 +0.92% settles Feb 11
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers